NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) —
Listing market: Euronext Growth
ISIN code: FR0010425595
| Date | Total variety of shares within the capital |
Total variety of voting rights |
| 09/30/2022 | 45,581,640 | 51,646,531 |
About Cellectis
Cellectis is a clinical-stage biotechnology company utilizing its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis makes use of an allogeneic method for CAR-T immunotherapies in oncology, pioneering the idea of off-the-shelf and ready-to-use gene-edited CAR T-cells to deal with most cancers sufferers, and a platform to make therapeutic gene modifying in hemopoietic stem cells for numerous illnesses. As a clinical-stage biopharmaceutical company with over 22 years of experience in gene modifying, Cellectis is creating life-changing product candidates using TALEN®, its gene modifying know-how, and PulseAgile, its pioneering electroporation system to harness the facility of the immune system to be able to deal with illnesses with unmet medical wants. As a part of its dedication to a remedy, Cellectis stays devoted to its aim of offering lifesaving UCART product candidates for a number of cancers together with acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and a number of myeloma (MM). .HEAL is a brand new platform focusing on hemopoietic stem cells to deal with blood issues, immunodeficiencies and lysosomal storage illnesses.
Cellectis’ headquarters are in Paris, France, with areas in New York, New York and Raleigh, North Carolina.
Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
For extra information, go to www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.
For additional information, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, [email protected]
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300
Investor Relation contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, [email protected]
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577
- Voting_Rights_PR_Sept_EN_docx
